Takeda sets December deadline for U.S. employees' Boston move

武田制药计划今年12月底之前搬空芝加哥工厂,预计将裁撤部分员工

2019-07-02 11:34:00 FiercePharma

本文共1138个字,阅读需3分钟

In the wake of its $64 billion buyout of Shire early last year, Takeda Pharmaceuticals outlined an ambitious consolidation of its operations in the Boston area. For the drugmaker’s 1,000 employees in the Chicago suburbs, that planned move now has a deadline. Takeda will empty its 77,000-square-foot Deerfield, Illinois headquarter facility by Dec. 31 as part of the relocation of its U.S. operations that the Tokyo drugmaker planned after it closed its purchase of Shire in January. Following the move of the 1,000 employees on site, the company is expected to put the Deerfield facility up for sale by March of next year. As part of the move, Takeda will temporarily reassign some of its Deerfield employees to work remotely while others will be assigned to a “transitional work location” in nearby Bannockburn, Illinois, according to Takeda spokesperson Julia Ellwanger. The company said it expects to lay off some of its Deerfield workers, but it didn't disclose job cut numbers. “In cases where there isn’t a solution that meets the business and/or an employee’s needs, the employee will be provided with severance and transition support programs,” Ellwanger said. “Because these discussions are ongoing, we are not providing numbers.” Takeda originally announced its relocation plans in September as it was working to close its massive buyout of Irish drugmaker Shire, which employed around 3,000 workers in the Boston area. Shire underwent an operations consolidation of its own in 2017, focusing its rare-disease research and U.S. commercial operations in Cambridge, and biologic and other manufacturing operations in Lexington.  In its first year with Shire on board, Takeda is expecting roughly flat growth for its pharma portfolio with generic competition and patent losses projected to take a big chunk out of the drugmaker’s profits. In the fiscal year ended in March, multiple myeloma blockbuster Velcade posted a 6.9% sales drop to 127.9 billion Japanese yen ($1.17 billion) following its loss of patent protection in 2018. Sales of Velcade, the predecessor to up-and-comer Ninlaro, were slated to drop by a precipitous 30% on the year, counting as a moral win for Takeda. Meanwhile, Ninlaro and inflammatory bowel disease med Entyvio each posted more than 30% sales growth on the year, helping prop up Takeda’s revenues in a year when net profits dropped 41.6% post-Shire buyout. With sales up and down and generics hitting its portfolio hard, Takeda could be in for a continued rough patch, especially with its gout drug Uloric losing traction with the FDA. In February, U.S. regulators slapped the drug with a black box warning for an increased risk of death and boxed the drug out from first-line treatment. That move limited the U.S. patient pool to roughly 8.3 million individuals, putting a hard cap on the drug’s sales forecast. Despite Uloric sales growing 9.1% on the year in 2018, Takeda forecast the drug could see a 30% plummet in the coming year.
在去年初以640亿美元收购夏尔(Shire)之后,武田制药( Takeda Pharmaceuticals )概述了其在波士顿地区业务的雄心勃勃整合。对于这家制药公司在芝加哥郊区的1000名员工来说,这一计划现在已经有了最后期限。 武田制药( Takeda )将在12月31日前将其位于伊利诺伊州鹿田( Deere field )的7.7万平方英尺的总部设施空出,这是该公司在1月份完成对夏尔(Shire)的收购后,计划对美国业务进行搬迁的一部分。在1,000名员工搬迁到现场后,预计公司将在明年3月前将 Deere 工厂出售。 根据武田发言人 Julia Ellwragan 的说法,作为这一举措的一部分,武田(Takeda)将临时调派部分迪尔菲尔德员工远程工作,而其他员工将被派往伊利诺伊州班诺伯恩附近的“过渡工作地点”。该公司表示,预计将裁员部分迪尔菲尔德员工,但没有披露裁员人数。 “如果没有满足业务和/或员工需求的解决方案,将为员工提供离职和过渡支持计划,”埃尔尔沃尔格林说。“因为这些讨论正在进行中,我们没有提供数据。” 武田制药( Takeda )最初在9月宣布了搬迁计划,当时该公司正努力完成对爱尔兰制药商夏尔(Shire)的大规模收购。 Shire 在波士顿地区雇用了大约3000名工人。夏尔(Shire)在2017年进行了自己的业务整合,重点是其在剑桥的罕见病研究和美国商业业务,以及在列克星敦的生物和其他制造业务。 在夏尔(Shire)上市的第一年,武田(Takeda)制药预计其医药产品组合的增长将大致持平,预计仿制药竞争和专利损失将在该公司利润中占很大比重。 在截至今年3月的财年中,多发性骨髓瘤大片 Velcade 在2018年失去专利保护后,销售额下降了6.9%,至1279亿日元(合11.7亿美元)。Velcade 的销售,前任上升和后来者 Ninalaro ,被认为是道德上的胜利武田(Takeda)一年急剧下降30%。 与此同时, Nillaro 和炎症性肠病 Entyvio 今年的销售额都增长了30%以上,帮助支撑了武田(Takeda)在 Shire 收购后净利润下降41.6%的一年里的收入。 随着销售额的上升和下降,仿制药的投资组合难以实现,武田(Takeda)可能会继续粗糙的补丁,特别是痛风药物 Uloric 失去了与 FDA 的牵引力。 今年2月,美国监管机构对该药发出黑匣子警告,称其死亡风险增加,并将该药从一线治疗中剔除。这一举措将美国患者的数量限制在830万人左右,对该药的销售预测设置了严格的上限。尽管 Uloric 的销售额在2018年同比增长9.1%,武田(Takeda)制药预计该药物在未来一年可能会暴跌30%。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文